Literature DB >> 3029273

Enolase isoenzymes as tumour markers.

K D Gerbitz, J Summer, I Schumacher, H Arnold, A Kraft, K Mross.   

Abstract

alpha- and gamma-enolase isoenzyme substance concentrations were measured in serum and plasma from healthy subjects and from 174 patients with different solid tumours. While alpha-enolase was found to be increased in the plasma of patients with tumours of quite different origin, gamma-enolase apparently reflected malignancies of the neuroendocrine system. Before the beginning of the cytotoxic therapy gamma-enolase was increased above the upper limit of the reference range (10 micrograms/l) in 27/27 patients (100%) suffering from small cell lung cancer. Most patients with squamous cell carcinoma of the lung or with prostatic cancer exhibited normal gamma-enolase, while both tumour types produced high plasma substance concentrations of the alpha-isoenzymes of enolase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3029273     DOI: 10.1515/cclm.1986.24.12.1009

Source DB:  PubMed          Journal:  J Clin Chem Clin Biochem        ISSN: 0340-076X


  6 in total

1.  RNAi-mediated knockdown of α-enolase increases the sensitivity of tumor cells to antitubulin chemotherapeutics.

Authors:  Elias Georges; Anne-Marie Bonneau; Panagiotis Prinos
Journal:  Int J Biochem Mol Biol       Date:  2011-10-21

2.  Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas.

Authors:  N Durany; J Joseph; E Campo; R Molina; J Carreras
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma.

Authors:  N Durany; J Joseph; O M Jimenez; F Climent; P L Fernández; F Rivera; J Carreras
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

4.  In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically.

Authors:  Jrhau Lung; Kuan-Liang Chen; Chien-Hui Hung; Chih-Cheng Chen; Ming-Szu Hung; Yu-Ching Lin; Ching-Yuan Wu; Kuan-Der Lee; Neng-Yao Shih; Ying Huang Tsai
Journal:  Drug Des Devel Ther       Date:  2017-11-16       Impact factor: 4.162

Review 5.  Reliability of S100B in predicting severity of central nervous system injury.

Authors:  Stephen M Bloomfield; James McKinney; Les Smith; Jonathan Brisman
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

6.  The automated processing algorithm to correct the test result of serum neuron-specific enolase affected by specimen hemolysis.

Authors:  Xiao-Min Liu; Xiao-Hua Liu; Min-Jie Mao; Yi-Jun Liu; Jun-Ye Wang; Shu-Qin Dai
Journal:  J Clin Lab Anal       Date:  2021-07-07       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.